ANTENGENE CORP. DL-0001 (722) - Total Liabilities
Based on the latest financial reports, ANTENGENE CORP. DL-0001 (722) has total liabilities worth €614.60 Million EUR (≈ $718.53 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore ANTENGENE CORP. DL-0001 annual equity growth to track the company's year-over-year net asset growth rate.
ANTENGENE CORP. DL-0001 - Total Liabilities Trend (2021–2025)
This chart illustrates how ANTENGENE CORP. DL-0001's total liabilities have evolved over time, based on quarterly financial data.
ANTENGENE CORP. DL-0001 Competitors by Total Liabilities
The table below lists competitors of ANTENGENE CORP. DL-0001 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Huizhong Instrumentation Co Ltd
SHE:300371
|
China | CN¥107.14 Million |
|
FutureCrest Acquisition Corp.
NYSE:FCRS
|
USA | $13.14 Million |
|
K-Fast Holding AB (publ)
ST:KFAST-B
|
Sweden | Skr19.09 Billion |
|
Global Indemnity Group, LLC Class A Common Stock
NASDAQ:GBLI
|
USA | $976.01 Billion |
|
Silvaco Group, Inc. Common Stock
NASDAQ:SVCO
|
USA | $34.74 Million |
|
GemVax&KAEL Co.Ltd
KQ:082270
|
Korea | ₩101.65 Billion |
|
Galata Wind Enerji Anonim Sirket
IS:GWIND
|
Turkey | TL6.55 Billion |
|
Fortress Value Acquisition Corp. V Class A Ordinary Shares
NASDAQ:FVAV
|
USA | $16.55 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down ANTENGENE CORP. DL-0001's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ANTENGENE CORP. DL-0001 stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.97 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.96 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.49 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ANTENGENE CORP. DL-0001's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ANTENGENE CORP. DL-0001 (2021–2025)
The table below shows the annual total liabilities of ANTENGENE CORP. DL-0001 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €614.60 Million ≈ $718.53 Million |
+24.43% |
| 2024-12-31 | €493.93 Million ≈ $577.46 Million |
+4.82% |
| 2023-12-31 | €471.20 Million ≈ $550.89 Million |
+9.88% |
| 2022-12-31 | €428.84 Million ≈ $501.36 Million |
+162.62% |
| 2021-12-31 | €163.29 Million ≈ $190.91 Million |
-- |
About ANTENGENE CORP. DL-0001
Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. The company's commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse lar… Read more